Shares of Teleflex Inc. TFX advanced 1.05% to $137.71 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 2.13% to 5,638.94 and ...

Teleflex's (NYSE: TFX) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant ...

NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex ...

Teleflex, whose shares sank nearly 20% Thursday, will acquire most of Biotronik’s vascular intervention assets. Teleflex also announced a CFO transition.

Teleflex (NYSE: TFX) announced today that it plans to separate its Urology, Acute Care and OEM businesses into a new publicly traded company.

Medical technology company Teleflex (NYSE:TFX) in Q4 CY2024 as sales rose 2.8% year on year to $795.4 million. Its non-GAAP profit of $3.89 per share was in line with analysts’ consensus estimates. Is ...

Teleflex is splitting its business into two independently traded entities, with a completion date set for mid-2026 ...

Teleflex plans to split into two companies by mid-2026, with RemainCo focusing on high-growth hospital markets and NewCo on urology and OEM. Teleflex will acquire Biotronik's Vascular Intervention ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $158.75, ...

Teleflex is separating into two publicly traded companies to optimize growth and shareholder value. The acquisition of Biotronik's Vascular Intervention expands Teleflex's presence in coronary and ...

Teleflex is splitting its business into two independently traded entities, with a completion date set for mid-2026. The company’s urology, acute care, and OEM businesses will be grouped under ...

Teleflex to create a new, independent publicly traded company ("NewCo”) consisting of Teleflex's Urology, Acute Care, and OEM businesses. Teleflex RemainCo ("RemainCo”) will consist of Teleflex's ...